Prostatype Genomics AB (publ) (PROGEN.ST)
Prostatype Genomics AB (publ) operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Nacka Strand, SE. The stock last traded at $0.12, up 5.63% on the session, giving a market capitalisation of $4.0M. Its beta of 1.40 implies it has historically moved more than the broad market.
Prostatype Genomics AB focuses on creating, marketing, and selling sophisticated prognostic gene tests. Their primary offering, the Prostatype Test System, combines genetic expression data with key clinical measurements such as PSA levels, Gleason Score, and Tumor Stage to determine a specific P-score. This advanced diagnostic tool is built upon a vast database of prostate cancer patients, providing crucial support for patients and medical practitioners when deciding on treatment strategies. Founded in 2007, the company is headquartered in Solna, Sweden.
Prostatype Genomics AB (publ) is most often compared with the following Healthcare names: